Evidence map›Paper›PMID 42227759›Full record

ArticleJournal of virology2026

Rab11Bis required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.

Allyson H Turner, Sara A Jaffrani, Hannah C Kubinski, Deborah P Ajayi, Matthew B Owens, Conor D Fanuele, Madeline P McTigue, Cailey L Appenzeller, Addington Bowling, Hannah W Despres and 5 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Allyson H Turner *Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.ORCID 0009-0009-9576-6095
Sara A Jaffrani *Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.ORCID 0009-0007-3684-0756
Hannah C KubinskiDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Deborah P AjayiDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Matthew B OwensDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Conor D FanueleDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Madeline P McTigueDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Cailey L AppenzellerDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Addington BowlingDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Hannah W DespresDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Madaline M SchmidtDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
David J ShirleyData Science Department, Faraday, Inc., Burlington, Vermont, USA.
Jessica W CrothersDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
Ramiro Barrantes-ReynoldsDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
Emily A BruceDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.ORCID 0000-0001-8391-370X

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kristen Pierce · 2018 to 2026
$24.9M
Understanding the Development of Mucosal Immunity to Poliovirus: Adjuvants and Modulation of the Enteric MicrobiotaK23AI175660 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Jessica W. Crothers · 2024 to 2026
$485k
Larner College of Medicine, University of VermontNIGMS NIH HHS P20 GM125498NIH HHS K23AI175660NIH HHS P20GM125498University of Vermont
6 · The paper itself

Abstract

Influenza A virus (IAV) depends on host proteins to complete several important functions, including trafficking viral proteins throughout the cell. Previous work has established a critical role for the cellular vesicular trafficking protein, Rab11A, in transporting the viral genome segments to the site of budding at the plasma membrane. While the role of Rab11A in IAV assembly is relatively well understood, very little is known about the function of a closely related isoform (Rab11B) during influenza virus infection. We have shown that both Rab11A and Rab11B are required for successful IAV infection by current H1N1 or H3N2 isolates. Cells in which either Rab11A or Rab11B were depleted failed to efficiently produce virus, with significant reductions in infectious titer. Surprisingly, our data revealed that recent (2022) H3N2, but not H1N1, isolates failed to efficiently produce viral proteins in single-cycle infections when Rab11B (but not Rab11A) was depleted. Flow cytometry analysis suggests that the defect in protein production is driven by a reduction in the total number of infected cells, rather than a decrease in viral protein production at the single-cell level. Using reverse genetics and "7+1" reassortant viruses, we mapped this Rab11B-dependent early defect in recent H3N2 isolates to the HA gene. RT-qPCR analysis of H3N2 virions bound to the cell surface showed a ~50% decrease in virus binding to the surface of cells depleted of Rab11B, but not Rab11A. Analysis of cell surface α2,6 and α2,3 sialic acids revealed no significant global change in sialic acid profile upon the depletion of Rab11B. As H3N2 virions could be removed by exogenous neuraminidase, the totality of these data suggests that the H3N2 failure to bind is the result of a loss of one (or more) specific sialylated cell surface protein(s) upon Rab11B depletion, rather than a decrease in bulk α2,6 sialic acid levels. These data suggest a novel role for Rab11B during viral entry that is specific to H3N2 isolates.IMPORTANCEInfluenza A is a major human pathogen, which poses risks through both the continuous circulation of "seasonal" influenza viruses (H1N1 and H3N2 subtypes) as well as the emergence of novel pandemic strains from animal hosts. Here, we demonstrate that contemporaneous H3N2 (but not H1N1) subtypes enter human lung cells through a Rab11B-dependent mechanism. This is distinct from the well-known role of Rab11A later in the life cycle, where it mediates the transport of viral ribonucleoprotein complexes to the site of virion assembly. These findings are relevant for assessing the risk that recently emerged zoonotic influenza viruses can enter human lung cells. Our work suggests that H1N1 and H3N2 viruses enter via different routes, which are not dependent on sialic acid levels. Our data provide important foundational information for the growing number of Rab11-dependent viruses, as it suggests that the Rab11 isoforms can affect both viral entry and viral exit.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, Humanrab GTP-Binding ProteinsVirus InternalizationAnimalsCell LineDogsHumansMadin Darby Canine Kidney Cellsrab11 GTP-Binding ProteinsVirus Replicationrab11 GTP-Binding Proteinsrab GTP-Binding ProteinsentryH3N2influenzaRab11ARab11Breceptor

Identifiers

PMID42227759
PMCPMC13289146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.